摘要
目的考察美罗培南联合莫西沙星治疗慢性阻塞性肺病并发感染性肺炎的临床疗效及安全性。方法收集慢性阻塞性肺病并发感染性肺炎患者92例,随机分为研究组和对照组。对照组46例患者给予莫西沙星治疗,研究组46例患者给予美罗培南联合莫西沙星治疗。分别比较两组患者治疗有效率、症状消失时间、病原菌清除率、药物敏感性和不良反应。结果研究组和对照组的治疗有效率分别为93.5%和87.0%,差异无统计学意义(χ2=0.49,P>0.05),体温恢复时间分别为(3.1±0.3)d和(3.5±0.5)d(t=-4.65,P<0.01)、咳嗽消失时间分别为(5.7±1.2)d和(6.5±1.5)d(t=-2.82,P<0.01)、湿啰音消失时间分别为(6.5±0.4)d和(7.2±0.7)d(t=-5.89,P<0.01)、白细胞恢复时间分别为(7.7±0.7)d和(8.5±0.6)d(t=-5.89,P<0.01),差异均具有统计学意义。病原菌清除率分别为91.3%和76.1%(χ2=3.90,P<0.05)、药物敏感性分别为87.0%和70.0%(χ2=4.09,P<0.05),差异均具有统计学意义。两组患者不良反应分别为13.0%和6.5%,差异无统计学意义(χ2=1.11,P>0.05)。结论使用美罗培南联合莫西沙星治疗慢性阻塞性肺病并发感染性肺炎可有效缩短症状缓解时间并增加病菌清除率,同时对不良反应的增加无统计学意义,安全有效具有临床应用价值。
Objective To study the clinical effects and safety of meropenem combined moxilfoxacin on pneumonia in patients with chronic obstructive pulmonary disease （COPD）. Methods Total of 92 COPD patients with pneumonia were randomly divided into study group and control group. There were 46 patients in control group whom were treated with moxilfoxacin while 46 patients in study group were treated with meropenem combined moxilfoxacin. The clinical efifciency, symptoms disappear time, pathogen clearance, drug sensitivity and adverse reaction between two groups were compared, respectively. Results The clinical efifciency in study group was 93.5%and 87.0%in control group, there was no signiifcant difference （χ2=0.49, P〉0.05）. The time of body temperature recovery were （3.1 ± 0.3） d and （3.5 ± 0.5） d, with signiifcant difference （t = -4.65, P 〈 0.01. The time of cough disappear were （5.7 ± 1.2） d and （6.5 ± 1.5） d, with signiifcant difference （t=-2.82, P〈0.01）. The time of moist sound were （6.5 ± 0.4） d and （7.2 ± 0.7） d, with signiifcant difference （t=-5.89, P〈0.01）. The time of leukocyte recovery were （7.7 ± 0.7） d and （8.5 ± 0.6） d, with signiifcant difference （t=-5.89, P〈0.01）. The pathogen clearance in study group and control group were 91.3%and 76.1%, with signiifcant difference （χ2=3.90,P〈0.05）. The drug sensitivity in study group and control group were 87.0%and 70.0%, with signiifcant difference （χ2=4.09, P〈0.05）. The adverse reaction rate were 13.0% and 6.5%, with significant difference （χ2= 1.11, P 〉 0.05）. Conclusions The treatment of meropenem combined moxilfoxacin on pneumonia in patients with COPD has a great clinical effects. The time of symptoms recovery is less than treatment of moxilfoxacin and the pathogen clearance is higher and has no serious advers reaction, which makes the treatment a safe and effetive.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2015年第1期71-74,共4页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
